Alzamend Neuro, Inc. is ranked as one of the cheapest stocks insiders are buying in March

From Yahoo Finance: 2025-03-28 10:42:00

The broader market index and blue-chip companies traded flat after solid gains Monday, while the NASDAQ Composite rose 0.2% due to hopes of looser U.S. tariffs.
March consumer confidence data showed a sharp decline in U.S. consumers’ short-term outlook on income, business, and job conditions, with investors wary of economic concerns and policy uncertainty.
Alzamend Neuro, Inc. ranks 10th among the 15 cheapest stocks insiders are buying in March, focusing on developing treatments for neurodegenerative and psychiatric disorders.
The company plans a Phase II clinical study of AL001 for Major Depressive Disorder, with insiders purchasing $14,621 worth of shares at an average price of $0.90 per share.
Alzamend Neuro stock has declined 12.07% since the beginning of the year, with one analyst rating it as a "Strong Buy" and a price target of $20.00.

Software stocks plummet due to AI concerns